Inside This Issue: Obesity
Top News Alerts: Product Updates, Deals & Financings
Company Spotlight: 7TM Pharma
Subscribe now to access over 40 articles covering developments in drugs, devices and diagnostics for the brain and nervous system.
Market Highlights: Boston Scientific Seeks Quick Fix by Selling Neuro Units
Struggling under liabilities from the 2006 acquisition of Guidant and yet another costly recall last month, Boston Scientific is feeling the pressure to make a dramatic change. It was widely reported this month that they have hired Bank of America to help them get a quick cash fix by selling their neuromodulation and neurovascular units. Boston Scientific needs to refinance $2.4 billion in 2011 and many fear the company will breach its covenants if it does not do something to raise cash.
Obesity: The Skinny on a Fat Market Opportunity
Being overweight or obese is associated with the availability of abundant, cheap, germ-free food. There have been several periods in recorded history where obesity was rampant in a particular civilization. These instances were recorded in art and literature and the condition was sometimes even considered a sign of success. In the 1900's, obesity in the US and Europe was the hallmark of lower social classes. That is no longer the case, and obesity is now common in all social classes, all races and ethnicities, and all age groups including children. This article outlines obesity treatments in development ...
7TM Pharma Regroups After "Next Gen" Obesity Targets Come Under Fire
7TM Pharma was founded in 2000 as a spinout from the University of Copenhagen by Professor Thue Schwartz and Dr. Christian Elling. NeuroInsights spoke with Dr. Elling to get an update on recent changes at the company. “When the company got started Schwartz and I had worked together for some time.” Elling says. “We were joined by local folks from the biotech industry, including our former CEO, Mette Kirstine Agger. The company was focused on a technology for drugs that act on GPCR's, also known as 7-transmembrane domain receptors or 7TM receptors, hence our name."
Companies Covered In This Issue Include: 7TM Pharma, AcelRx, Affiris, Alimera, Alkermes, Allon, Amarantus, Amylin, Arena Pharma, AstraZeneca, Axeron, Baxter, Biocortech, BrainCells, Inc, Checkpoint Surgical, Cerimon, Cognifit, D-Pharm, Eli Lilly, Enteromedics, Euthymics, Evotec, GE Healthcare, Gelesis, GI Dynamics, GSK, Icagen, Intrapace, IScience Interventional, IMI, Leptos Biomedical, Marc Polo Pharma, MAP Therapeutics, Medtronic, Merck, Mylan, Nano Retina, Nautilus, NeuroHealing, Neurogesx, Neuronetics, NeuroSearch, Neurimmune, Novarits, Nupathe, Orexigen, Orion, Posit Science, Pfizer, Proteus, Rexahn, Satori, Sinapsis, StemCells, Inc., Stemedica, Sun Pharma, Synosia, Upsher-Smith, Vivus, Xanodyne, Xenome
Subscribe Now:
|
|
